Even though all IFNs utilize STAT1 as a signaling mediator, type I and II IFNs exert opposing effects on the progression of the demyelinating, T cell-mediated autoimmune disease multiple sclerosis (MS) [11]. The gene discussed is STAT1; the disease is myeloid sarcoma.